Amyrt Pharma announced that The Lancet Diabetes & Endocrinology has published the full results of the global Phase 3 MPOWERED clinical trial that compared Mycapssa (oral octreotide capsules) to long-acting injectable Somatostatin Receptor Ligands (iSRLs) for maintenance of biochemical response in patients with acromegaly. The MPOWERED trial was designed to support the marketing authorization application (MAA) for Mycapssa to the EMA which is currently under evaluation.
The 5 lined up for their IPO runs this week are hunting more than $500 million and proof that they share a market value of about $4 billion. Roughly half of that is laid out in Rubius’ S-1 as that biotech hunts up $200 million.